Abstract
Within among assessments, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) reviews patient-relevant outcomes that include mortality, morbidity (symptoms and complications), and health-related quality of life (HRQoL). The latter two require patient-reported outcomes (PRO’s) data. There is a dearth of systematic evidence on the methodological approaches to reporting PRO data within IQWiG appraisals. This study aimed to review the IQWiG decisions regarding patient-relevant outcomes supporting oncology treatments based on an example of triple-negative breast cancer (TNBC).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
